Content Type: Article

  • HRSA Confirms 340B Off-Site Facility Policy, Delays Enforcement

    HRSA Confirms 340B Off-Site Facility Policy, Delays Enforcement

    ARTICLE / CLIENT ALERT

    HRSA Confirms 340B Off-Site Facility Policy, Delays Enforcement

    October 30, 2023

    Read time: 7 min

    Key takeaways
    Overview

    On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, an off-site outpatient facility of a covered entity (commonly referred to as a “child site”) must be reimbursable on the covered entity’s most recently filed Medicare cost report (MCR) and listed in the Office of Pharmacy Affairs Information System (OPAIS) as a child site of the covered entity. HRSA explained it had determined to end the “waiver” of these requirements implemented during the COVID-19 public health emergency (PHE). HRSA is giving hospitals 90 days to come into compliance with the notice’s requirements. Hospitals with unregistered child sites should consider whether it is appropriate to take further action pursuant to the notice at this time.

    In depth

    Background

    In 1994, HRSA issued guidance on the participation of covered entities’ off-site outpatient facilities in the 340B program. Those guidelines required hospital covered entities to take the following actions before a child site could be considered part of the covered entity:

    • List any off-site outpatient facility as reimbursable on the hospital’s most recently filed MCR
    • Include associated costs and charges for the facility on the MCR most recently filed with the Centers for Medicare and Medicaid Services (CMS)
    • Register the facility in OPAIS as a child site of the covered entity

    Under the 1994 guidance, once fully registered in OPAIS, such facilities were eligible for 340B discount pricing because HRSA considered them “an integral component of” the covered entity eligible for participation. However, because cost reporting and OPAIS registration may not occur until almost two years after a child site opens, this policy deprives covered entities of the ability to purchase 340B drugs at these sites for an extended period of time after opening, even though the Medicare program may consider these sites part of the hospital immediately upon opening.

    COVID-19 Policy

    On June 6, 2020, in response to the COVID-19 PHE, HRSA posted to its website a COVID-19 Resources page that announced “waivers” for certain 340B program requirements, including certain auditable record requirements and volunteer health professionals. Separately, an “FAQs” section of the website addressed “some general frequently asked questions (FAQs) related to COVID-19.” HRSA explained in one such FAQ that “for hospitals who are unable to register their outpatient facilities because they are not yet on the most recently filed Medicare Cost Report, the patients of the new site may still be 340B eligible to the extent that they are patients of the covered entity.” In other words, an outpatient facility was no longer required to be listed as a reimbursable cost on a covered entity’s most recently filed cost report and registered in OPAIS to be considered part of the 340B covered entity. HRSA did not indicate it was temporarily “waiving” the MCR filing requirement, and in subsequent communications, HRSA officials stated that the eligibility approach announced on the COVID-19 resources page reflected a permanent policy change that would extend beyond the PHE.

    Notice Purports to Recharacterize COVID-19 Policy

    In its October 26 notice, HRSA purports to recharacterize the eligibility approach announced in 2020 as a temporary “waiver.” HRSA noted that the “burden of registration and including a facility in the next filed MCR does not take significant resources, and hospitals making good faith efforts to come into compliance should be able to adjust operations within this transition time period.” The notice did not support this statement with evidence, nor did it acknowledge that the cost report and registration requirements can delay access to 340B drug pricing by almost two years, requiring many covered entities to pay drug manufacturers millions of dollars in higher drug prices during the interim period.

    Notice’s Enforcement Delay

    Stating that some covered entities “believed the waiver would continue indefinitely,” the notice provided a transition period for covered entities to bring their off-site facilities into compliance with the 1994 requirements. The transition period, requirements for hospitals, and procedures for compliance differ based on the child site’s circumstances:

    • Sites currently listed on the hospital’s most recently filed MCR with associated outpatient costs and charges, but not yet registered in OPAIS:
      • May continue to use 340B drugs for patients
      • Must register in OPAIS within the next 340B program quarterly registration (January 1–16, 2024)
    • Sites not listed on the hospital’s most recently filed MCR and not registered in OPAIS:
      • May continue to use 340B drugs for patients if:
        • They opened prior to October 27, 2023, and
        • They began using 340B drugs prior to October 27, 2023
      • Must email HRSA at 340Bcompliance@hrsa.gov prior to January 25, 2024, with the following:
        • Name of the child site
        • Date the child site will be listed on the hospital’s MCR (which must be the next filed MCR) with associated outpatient costs and charges
        • Date the hospital will register the child site in OPAIS
    • Sites not in compliance with requirements that otherwise do not fall under either of the above categories:
      • Must stop using 340B drugs prior to January 25, 2024

    HRSA did not invite comment to the notice.

    Analysis

    The notice reiterates HRSA’s position on unregistered child site eligibility and provides HRSA’s rationale for reverting to its 1994 policy after the PHE ended. HRSA indicated in May that it would revert to the 1994 policy when the PHE ended by removing the COVID-19 FAQs from its website and subsequently issuing audit findings deeming unregistered child sites noncompliant with the 340B statute’s requirements. However, at that time, HRSA did not set forth its rationale for reverting to the 1994 policy.

    The notice does not explain how the 1994 eligibility requirements are consistent with the 340B statute’s covered entity and hospital definitions, as currently interpreted by CMS, nor does it explain how HRSA could have temporarily waived the 1994 registration requirements if the requirements were, in fact, established by statute—the 340B statute does not authorize HRSA to waive statutory requirements. The notice references CMS’s Medicare provider-based standards that interpret the statutory definition of a hospital for enrollment and reimbursement purposes, but the notice does not attempt to reconcile HRSA’s differing interpretation of the same statutory text.

    HRSA’s rationale for reverting to its 1994 policy focuses on potential program integrity concerns arising during the PHE, asserting that the 2020 policy “added risk and complexity to HRSA’s ability to effectively oversee ongoing compliance in the 340B program.” HRSA noted that it had “significant challenges” determining compliance for sites that were not reported on a cost report and registered in OPAIS because “it was unclear whether the unregistered sites would ever be eligible and an integral part of a 340B hospital.” HRSA did not consider relying on satisfaction of the Medicare provider-based rules to determine if an unregistered site was an integral part of a 340B hospital, even though such satisfaction is the standard CMS uses to make the same determination. HRSA also did not indicate that any of its program integrity efforts have actually identified an unregistered child site that was not “an integral part of the 340B hospital.”

    Covered entities with unregistered child sites that are in a position to comply with the notice’s options and timelines may choose to do so to reduce the risk of audit and adverse audit findings. However, the notice indicates that HRSA is taking the position that covered entities with child sites that will appear on their next MCR are subject to HRSA’s 1994 policy, and under that policy are unable to purchase 340B drugs for these locations before the locations are reported on the MCR and registered in OPAIS.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Paul W. Hughes

    Partner

    Washington, DC

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    Charlie Seidell

    Partner

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • California Expands Paid Sick Leave to Five Days Per Year

    California Expands Paid Sick Leave to Five Days Per Year

    ARTICLE / CLIENT ALERT

    California Expands Paid Sick Leave to Five Days Per Year

    October 30, 2023

    Read time: 8 min

    Key takeaways
    Overview

    On October 4, 2023, California Governor Gavin Newsom signed Senate Bill 616 (SB 616) into law, officially expanding the Healthy Workplaces, Healthy Families Act of 2014 (HWHFA), California’s paid sick leave law. Effective January 1, 2024, California employers must begin providing eligible employees with at least five days or 40 hours of paid sick leave, increased from the previous minimum of three days or 24 hours.

    In depth

    THE LAW

    The HWHFA covers all employees who work at least 30 days in California for an employer and applies to all employers with at least one covered employee. It generally provides that any covered employee may take paid sick leave for permitted purposes, including a medical need (for themselves, a covered family member or a designated person) or for purposes related to domestic violence, sexual assault or stalking.

    The law also sets out additional requirements related to paid sick leave. For example, employees must provide reasonable advance notice of the need to take paid sick leave, unless the need is unforeseeable, and generally, employers are not permitted to require documentation verifying the need for leave. In addition, employers have various posting and notice obligations as well as the obligation to reinstate accrued and unused paid sick leave for employees who have been rehired within one year from the date of separation.

    While SB 616 leaves these aspects of the HWHFA unchanged—for instance, employers do not have an obligation to pay out unused paid sick leave at termination—it does make many crucial changes:

    Current Law New Law as of Jan. 1, 2024
    Frontload Method
    (lump sum at the beginning of the year)
    Three days or 24 hours Five days or 40 hours.
    Employers must provide a minimum of five days or 40 hours of paid sick leave, whichever is greater, per year or 12-month period.
    Accrual Method Rate
    (earn sick time each pay period)
    Three days or 24 hours by the 120th day of employment, calendar year or 12-month period Five days or 40 hours by the 200th day of employment, calendar year or 12-month period.
    Employers must provide a minimum of three days or 24 hours of accrued sick leave by the 120th day of employment or each calendar year (or 12-month period), and additionally must provide another 16 hours by the 200th day of employment or calendar year (or 12-month period). Given the rate of accrual, it is important for employers to also consider permitted accrual and use caps within their policies.
    Continuous Accrual Cap Six days or 48 hours 10 days or 80 hours.
    For employers who use accrual methods, unused paid sick days must still be carried over to the following year of employment for eligible employees. The new continuous accrual cap is 10 days or 80 hours of paid sick leave, whichever is greater.
    Use Caps
    (per year of employment, calendar year, or 12-month period)
    Three days or 24 hours Five days or 40 hours.
    Note that employers may still limit their employees’ use of paid sick leave to the minimum of five days or 40 hours per year.

    *Note, this chart identifies key components of the California law, but it does not consider requirements of various local jurisdictions, which may differ.

    • Extended Protection to CBA-covered Employees: SB 616 extends some HWHFA protections to union employees covered by collective bargaining agreements (CBAs). Namely, CBA-covered employees must now be allowed to take paid sick leave for HWHFA-covered reasons, cannot be required to find a replacement for the days they take their leave and cannot be retaliated or discriminated against for doing so.
    • Preemption: SB 616 seeks to establish greater uniformity between state and local paid sick leave laws, and it thus explicitly preempts local ordinances that are contrary to the HWHFA with respect to the following issues:
      • Rate of Pay: Employers must calculate paid sick time for nonexempt employees in one of the following three ways:
        1. In the same manner as the regular rate of pay for the workweek in which the employee uses paid sick time, whether or not the employee actually works overtime in that workweek;
        2. By dividing the employee’s total wages, not including overtime premium pay, by the employee’s total hours worked in the full pay periods of the prior 90 days of employment; or
        3. In the same manner as the employer calculates wages for other forms of paid leave.
      • Timing of Pay: Employers must provide payment for sick leave taken by an employee no later than the payday for the next regular payroll period after the sick leave was taken.
      • Written Notice: Employers must provide employees with written notice that sets forth the amount of paid sick leave available, or paid time off that the employer provides in lieu of sick leave, for use on either the employee’s itemized wage statement or in a separate writing provided on the designated pay date with the employee’s payment of wages. If an employer provides unlimited paid sick leave or unlimited paid time off to an employee, the employer may satisfy this section by indicating “unlimited” on the notice or the employee’s itemized wage statement.
      • Advance Leave: Employers may lend paid sick days to an employee in advance of accrual at the employer’s discretion and with proper documentation.
      • Advance Notice: Employees must provide reasonable advance notification of their need to take paid sick leave if the need is foreseeable. If the need for paid sick leave is unforeseeable, the employee need only provide notice “as soon as practicable.”
      • Rehiring: Employers are not required to pay out accrued, unused sick leave upon an employee’s termination. If an employee separates from an employer and is rehired by the same employer within one year from the date of separation, their previously accrued and unused paid sick days must be reinstated. However, reinstatement is not required if the employer paid out the employee’s accrued, unused paid sick time at separation.

    PENALTIES FOR NONCOMPLIANCE WITH THE NEW REQUIREMENTS OF SB 616

    The HWHFA does not directly permit a private right of action by an aggrieved employee; it expressly limits remedies to equitable, injunctive or restitutionary relief.

    However, the California Court of Appeal Fourth Appellate District recently ruled in April 2023 that employees can enforce the HWHFA through a Private Attorneys General Act action. While the Fourth District’s decision stands apart from other federal and state court decisions, employers should expect further litigation on this issue and take care to comply closely with SB 616.

    Also, employers should note that the penalties for violating the written notice requirement described above would be imposed in lieu of penalties for a violation of California Labor Code Section 226, which requires itemized wage statements.

    SB 616’S UNSETTLED QUESTIONS

    • Safe Harbor Provision: Currently, there is no safe harbor provision or “ramp up” period for employers to plan and effectuate new policies and procedures that comply with SB 616. We advise that employers prepare for compliance as soon as possible.
    • Timing of Verification Documentation: Since the California labor commissioner’s interpretation of the HWHFA prevents employers from requiring documentation to substantiate an employee’s need to take paid sick leave, most employers have implemented a practice of requiring a doctor’s note only after the third day of leave. With SB 616, employers may now need to wait until after the fifth day of an employee’s paid sick leave to ask for any kind of substantiation.

    PRACTICAL CONSIDERATIONS AND NEXT STEPS

    As employers prepare for compliance and implementation of these new requirements, they should consider the following:

    • Employers with combined PTO policies (i.e., that combine sick leave, vacation and other types of leave into one “bucket”) should consider reviewing and updating policies as necessary to confirm that they continue to meet the new minimum California requirements for paid sick leave.
    • Employers should coordinate with their payroll providers to confirm that their payroll and wage statements will be adjusted to meet the new requirements.
    • Employers with CBA-covered employees should consult with labor counsel and take special care in reviewing applicable CBAs and their policies and procedures, specifically to ensure that unionized employees can take paid sick leave for qualifying reasons.
    • Because SB 616 partially preempts local ordinances, employers should also review any local paid sick leave ordinances that may apply to their workforce based on the city and county they operate in.

    For assistance with SB 616 and HWHFA compliance and implementation, please contact McDermott’s Employment Practice Group.

    Authors

    Laurie A. Baddon

    Partner

    Los Angeles, Orange County

    More insights

  • Lowest-risk Clinical Trials Will Benefit From a New Notification Scheme and a Shorter Period for Application Processing

    Lowest-risk Clinical Trials Will Benefit From a New Notification Scheme and a Shorter Period for Application Processing

    ARTICLE / CLIENT ALERT

    Lowest-risk Clinical Trials Will Benefit From a New Notification Scheme and a Shorter Period for Application Processing

    October 30, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On 12 October 2023, the Medicines and Healthcare products Regulatory Agency (the MHRA) announced that the healthcare and life sciences sector will benefit from a new streamlined notification scheme for lowest-risk clinical trials (the Scheme). The Scheme will see the lowest-risk clinical trials processed by the MHRA in less than 14 days.

    The current legislation that governs the regulation of clinical trials in the UK is the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is based on the EU Clinical Trials Directive. Following Brexit, the UK is in the process of overhauling its clinical trials regulatory regime to deliver a world-class regulatory environment for clinical trials to support the safe development of innovative medicines for the benefit of patients and public health.

    In depth

    As discussed in our previous updates, to this end, the MHRA consulted on various proposals for legislative change, which would be made using powers set out in the Medicines and Medical Devices Act 2021 (the Consultation). The MHRA designed the proposals to:

    • Ensure patients safety and bring the benefits of clinical trials to everyone;
    • Create a proportionate and flexible regulatory environment;
    • Cement the UK as a destination for international trials; and
    • Enable innovation.

    The consultation closed in March 2022, and the new regulations have not yet been published.

    The Scheme

    Under the Scheme, the MHRA will process initial clinical trial authorization (CTA) applications for eligible clinical trials much quicker – within 14 days instead of the usual 30 days. About 20% of UK initial clinical trial applications are expected to be eligible.

    The Scheme currently only applies to CTA applications for Phase 4 and certain Phase 3 clinical trials deemed to be of lower risk; it does not include CTA applications for first in human (FIH), Phase 1 or Phase 2, or amendments at this time. Additional MHRA’s criteria apply as well.

    Phase 4 trials (post-marketing or surveillance trials of licensed medicines) must meet both of the following criteria:

    • All investigational medicinal products (IMPs) are licensed and used according to the relevant UK, USA, or EU marketing authorisation (except for placebo); and
    • There are no ongoing safety concerns with the IMP(s).

    Phase 3 (pivotal pre-marketing trials and evaluate the efficacy and safety of the drug) must meet at least one of the following criteria:

    • The trial is already approved in the USA or EU based on the same documentation (the same protocol and/or investigator’s brochure and/or IMP dossier).
    • The MHRA have approved in the last 2 years a previous phase 3 clinical trial of the IMP(s) at the same dose (or a higher dose), dosing frequency (or a higher frequency) and route of administration, and for the same indication (even if the trial was with a different sponsor) and utilising the same manufacturing process.
    • IMPs are licensed and used according to the relevant UK, USA, or EU marketing authorisation (except for placebo).
    • In addition, to be eligible for the scheme a Phase 3 trial must not include any of the following:
      • Complex, innovative trial design (e.g. basket, umbrella and platform) that allows for prospective major adaptations such as the addition of indications or IMPs via future amendments;
      • Includes paediatric participants;
      • Includes pregnant or breastfeeding participants;
      • IMP is first in class;
      • IMP is an advanced therapy medicinal product (ATMP).

    The MHRA has said that it will keep the criteria for notification of clinical trials under continual review.

    A favourable opinion from a Research Ethics Committee (REC) is still required for eligible trials, and although applications under the Scheme are submitted via the combined review process using the Integrated Research Application System (IRAS); the REC opinion is not part of the Scheme, and therefore the 14-day timeframe does not apply to the REC although the HRA said, at the time of the announcement, that the HRA are keen to explore how the fast-track Research Ethics Service can complement the Scheme.

    The Scheme is meant to support the UK government’s ambition to be one of the best countries in the world to conduct clinical research for patients and researchers by introducing more flexibility and making decisions based on an assessment of risk will help streamline processes for those running trials. The government plans to move away from ‘one size fits all’ legislation and introduce measures to enshrine proportionality.

    Authors

    Sharon Lamb

    Partner

    London – 22 Bishopsgate

    Bella North

    Senior Associate

    London – 22 Bishopsgate

    More insights

  • Bulletin Concurrence IX

    Bulletin Concurrence IX

    ARTICLE

    Bulletin Concurrence IX

    October 2023

    Read time: 2 min

    Key takeaways
    Overview

    We are delighted to share the ninth Bulletin Concurrence which aims to keep you up to date with the key developments in competition law over the third quarter of 2023.

    Read the full Bulletin (in French) here.

    In depth
    Authors
    More insights

  • UK LLPs ̵ Salaried Member Rules: UT Decision in HMRC v BlueCrest Capital Management (UK) LLP

    UK LLPs ̵ Salaried Member Rules: UT Decision in HMRC v BlueCrest Capital Management (UK) LLP

    ARTICLE / CLIENT ALERT

    UK LLPs ̵ Salaried Member Rules: UT Decision in HMRC v BlueCrest Capital Management (UK) LLP

    October 27, 2023

    Read time: 5 min

    Key takeaways
    Overview

    The keenly awaited decision of the Upper Tribunal (“UT”) in HMRC v BlueCrest Capital Management (UK) LLP provides helpful guidance for any LLP intending that some or all of its members fall outside the scope of the salaried member rules.

    The Salaried Member Rules and Why They Matter

    UK LLPs are widely-used as a vehicle of choice for investment management firms in the private capital sector. For tax purposes, a UK LLP is generally treated as a partnership and, subject to the following, its members are generally treated as self-employed partners.

    The salaried member rules treat an individual member of an LLP as a ‘salaried member’, and thus as an employee for tax purposes (subject to PAYE and employer/employee NIC), if each of the three following conditions is met. In brief, these are:

    • Condition A (‘disguised salary’) – at least 80 percent of the member’s reward is fixed or, if not fixed but variable, varies without reference to the overall profits/losses of the LLP.
    • Condition B (‘significant influence’) – the member does not have ‘significant influence’ over the affairs of the LLP.
    • Condition C – the member’s capital contribution to the LLP is less than 25 percent of the member’s ‘disguised salary’.

    If any one of the conditions is not met, then the individual is not a salaried member. Most investment management firms look to structure their affairs so that one or both of conditions A and B are not met.

    The First Tier Tribunal (‘FTT’) Decision

    BlueCrest appealed HMRC’s determination that certain individual LLP members were salaried members. The appeal only concerned the application of Conditions A and B. (It was common ground that the individual members all met Condition C).

    In its first instance decision (released on 29 June 2022), the FTT held that all the individual LLP members who were the subject of the appeal met Condition A and those who were not portfolio managers, or were portfolio managers with capital allocations of less than $100 million, also met Condition B and were thus ‘salaried members’. Portfolio managers with capital allocations of $100 million or more, and ‘desk heads’, did not meet Condition B and thus were not ‘salaried members’.

    UT Decision

    Both HMRC and BlueCrest appealed the FTT decision.

    In rejecting all 11 grounds of appeal: 2 (re Condition A) from BlueCrest and 9 (re Condition B) from HMRC and upholding the FTT decision, the UT held that in relation to:

    • Condition A, there needs to be a meaningful link between at least 20 percent of an individual’s remuneration and the overall profits and losses of the LLP; the link cannot simply be that if there is less profit available for distribution, the individual member will receive a lesser amount.
    • Condition B, ‘significant influence’ need not be over the entirety of the affairs of the LLP, or of a managerial nature: operational, financial or managerial responsibility over one or more aspects of the affairs of an LLP may give rise to ‘significant influence’.

    Having noted the ‘acutely fact sensitive’ nature of the FTT’s decision, as well as the very limited circumstances in which an appellate court, such as the UT, can intervene, the UT rejected (variously) the ‘misconceived’ and ‘highly unrealistic’ way in which HMRC sought to apply the rules, noting that its approach effectively sought ‘to write additional words into Condition B’.

    While FTT decisions have no precedent value, the UT decision provides helpful guidance, in particular in respect of Condition B and the proper construction of the terms ‘affairs’ and ‘influence’, and supports the approach that ‘significant influence’:

    • can be established by reference to actual (de facto) influence which may not derive from the LLP agreement;
    • is substantively determined by reference to an individual’s activities and not simply by reference to any ‘crude’ threshold such as a minimum capital allocation; and
    • is not determined by the application of any ‘rigid test,’ but rather by applying the words of Condition B to the facts of the case.

    Conclusion

    Whilst the situation of each individual member in each LLP will be highly fact-specific, our view remains that LLP compensation arrangements can, with appropriate care and planning, be structured so as to incentivise individual and/or team performance in such a way that Condition A is not met. Similarly, albeit always subject to a careful analysis of the facts and circumstances, we consider that the operation of an LLP can be structured so that relevant individuals do in fact have “significant influence” and hence Condition B is not met, provided that the LLP has genuinely sought to distinguish between true partners and ‘salaried members’ by drawing the demarcating line at the appropriate level. Importantly, the relevant test should not be applied in the restrictive manner sought by HMRC in BlueCrest.

    If you would like to discuss any aspect of the salaried members rules as they apply in your particular circumstances, please contact Dan Roman, Nick Fagge or your usual Schulte contact.


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Nick Fagge

    Partner

    London – One Eagle Place

    More insights

  • OIG to Pathology Lab: Don’t Pay for Services You Don’t Need

    OIG to Pathology Lab: Don’t Pay for Services You Don’t Need

    ARTICLE / CLIENT ALERT

    OIG to Pathology Lab: Don’t Pay for Services You Don’t Need

    October 25, 2023

    Read time: 8 min

    Key takeaways
    Overview

    In September, the US Department of Health and Human Services Office of Inspector General (OIG) issued an unfavorable advisory opinion to a pathology laboratory concerning a proposed services arrangement with referring pathology laboratories. This result was unsurprising, because the services contracted for were not commercially reasonable. The opinion allowed OIG to repeat its skepticism of arrangements that carve out federal healthcare program business because of the potential for a “pull-through” effect (in which the arrangement may influence or result in the other party sending federal healthcare program business to the counterparty). The opinion provides several lessons in how to properly structure legitimate pathology services arrangements.

    In depth

    BACKGROUND

    Anatomic pathology laboratories (path labs) and physician practices routinely enter into arrangements whereby a path lab receives a request from a physician practice to perform either the technical component (TC) of a pathology service (e.g., sample preparation and staining) or the professional component (PC) (i.e., reading and interpreting a stain), or both. Although most payors expect each party to bill and collect for their own individual services pursuant to their own payor agreements, some payors, including Medicare, allow for the physician practice or path lab to bill for both components of the pathology service (global billing) when certain contractual and billing requirements are met.

    ABOUT ADVISORY OPINION 23-06

    On September 28, 2023, OIG issued an unfavorable advisory opinion (Advisory Opinion 23-06) regarding a proposal for global billing of pathology services by a requestor, an independent path lab. In the proposed arrangement, a physician practice or non-physician-owned path lab would refer a pathology service to the requestor to perform the TC and PC. The requestor would then contract the performance of the TC back to the physician practice or non-physician-owned path lab. The requestor would bill payors globally for the pathology service, receive payment for the global claims and remit payment back to the physician practice or non-physician-owned path lab for the TC of the test at a fair-market-value, per-test rate. Referring path labs would be attracted to the proposal because they lack in-network contracts with certain commercial insurers and thereby could benefit from referring to laboratories, including the requestor, that have favorable in-network contracts with commercial payors.

    Individuals may request an advisory opinion in order to secure a negative opinion from the OIG. Here, the requestor certified to facts that guaranteed an unfavorable result, including that:

    • The personal services and management contracts safe harbor was not met because the services the referring path lab would perform exceeded those reasonably necessary to accomplish the commercially reasonable business purpose of the arrangement
    • In most cases, the requestor has the capacity to provide the TC itself and would do so at a lower cost than it would pay to the referring laboratories
    • Although the proposed arrangement would carve out services provided to federal healthcare program beneficiaries, the nature of referrals to path labs would likely lead to referrals of federal healthcare program business. Requestor predicted that if it did not enter into the proposed arrangement, it likely would not receive a significant volume of referrals of federal healthcare program business from these labs

    OIG ANALYSIS

    OIG concluded that the arrangement would implicate the Anti-Kickback Statute (AKS) because it would involve the requestor paying a party that is in a position to refer services that may be paid, in whole or in part, by a federal healthcare program. The requestor stated that referring labs would be primarily motivated to engage the requestor to perform path lab services due to its favorable in-network contracts with commercial insurers. However, OIG could not conclude that carving out federal healthcare program business would insulate the arrangement from liability under the AKS and that there would be no nexus between the payment as part of the proposed arrangement and potential referrals to the requestor for services reimbursable by federal healthcare programs.

    In its analysis, OIG reiterated its longstanding concern about arrangements that carve out federal healthcare program business or beneficiaries in an attempt to justify questionable compensation arrangements, citing a 2014 OIG advisory opinion and noting that such arrangements can disguise remuneration for federal healthcare program business through payments purportedly related to non-federal healthcare program business. This is because the remuneration paid from the requestor to laboratories may increase the likelihood that these entities would order services from the requestor that are billable to federal healthcare programs simply out of convenience and familiarity. Indeed, the requestor predicted that if it did not enter into the proposed arrangement, it would be unlikely to receive a significant volume of federal healthcare program referrals.

    OIG further concluded that the arrangement would not be protected by the AKS personal services and management contracts and outcomes-based payment arrangements safe harbor, because the requestor was unable to certify that the aggregate services contracted for would not exceed those that are reasonably necessary to accomplish the commercially reasonable business purpose of the services. Because the requestor generally could perform both the TC and PC in house—and do so more efficiently and cost-effectively than by “purchasing” the TC from a referring laboratory—the OIG found it difficult to discern any commercially reasonable business purpose for which the requestor would enter into the arrangement, other than the possibility of inducing referrals of patients, including federal healthcare program beneficiaries.

    KEY TAKEAWAYS

    • Given the fact that the services contracted for were not commercially reasonable, OIG had no choice but to issue an unfavorable opinion. When reviewing unfavorable opinions, keep in mind that requestors can withdraw an opinion request if OIG informs them that the opinion will be unfavorable. As with many negative advisory opinions, the requestor in this case may have had some other purpose behind continuing to seek an unfavorable opinion, such as aiming to prevent competitors from engaging in the proposed practices or establishing that an arrangement into which the requestor was being asked to enter would be prohibited by OIG.
    • The OIG has remained staunchly skeptical of arrangements that carve out federal healthcare business as a way to minimize risk under the AKS. From OIG’s perspective, the commercial payment could act as a “pull-through” inducement for federal healthcare program business. If there are no federal healthcare program referrals made between the parties, then the AKS would not be implicated. If there are federal healthcare program referrals, there may be some business relationships where a carve-out makes sense, but such carve-outs should be followed in order to achieve the purpose of protecting the arrangement from AKS risk. Here, the requestor negated the ability to take such a position by saying that it was likely that requestor would receive more federal healthcare program referrals as a result of the arrangement and likely would not receive such referrals if it did not enter into the arrangement.
    • OIG did not address whether its conclusion would have been different if the requestor disclosed that it performed and billed the TC by using claims modifiers rather than billing globally, though this was not an option for the requestor, because the referring lab was out of network. We speculate that the attempt to mask the arrangement from payors may have been a sufficiently bad fact to demonstrate malfeasance and raise OIG’s scrutiny. Commercial payors do not always allow in-network providers to bill for services performed by other entities, which could be viewed as mitigating the remunerative value of the arrangement.
    • An undergirding intent of the arrangement may have been for referring laboratories to “price shop” for the most favorable commercial insurer contract rates. This intent does not necessarily implicate the AKS, because it is unrelated to federal healthcare program referrals. However, it may raise commercial contract, state law and antitrust risks.
    • As described in the background, agreements between a physician practice and a path lab to purchase TC or PC are common in the industry for myriad reasons, including a physician practice not having in-house capabilities to perform special pathology stains. Such arrangements are not specifically implicated by this advisory opinion. Nevertheless, providers should evaluate their purchased-services arrangements in light of the facts and risks identified in this advisory opinion to ensure that they are commercially reasonable, and providers should note that such arrangements may not be permissible under commercial payor rules.
    • As always, parties to any arrangement for purchased services, or where one party is billing for services provided by another, should not attempt to characterize the arrangement in a manner that is known to be false to the participants. In this proposed arrangement, it would be nonsensical for a physician office to refer the performance of both the TC and PC of a pathology service to a path lab and then require the path lab to refer the TC back to the physician office. Parties should not assume that a regulator would not be able to immediately identify that the arrangement is in fact for referral of the PC only. Of course, the requestor here likely understood the inherent problem in the arrangement because the requestor certified that it did not need the services of the practice to achieve commercially reasonable purposes.
    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    MaryKathryn Hurd

    Senior Knowledge Management Manager

    Washington, DC

    More insights

  • Opportunity Knocks: At Long Last, IRS Determination Letter Program Opens for 403(b) Plans

    Opportunity Knocks: At Long Last, IRS Determination Letter Program Opens for 403(b) Plans

    ARTICLE / CLIENT ALERT

    Opportunity Knocks: At Long Last, IRS Determination Letter Program Opens for 403(b) Plans

    October 24, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The Internal Revenue Service (IRS) has opened a new determination letter approval program for 403(b) retirement plans. The program allows sponsors of certain individually designed 403(b) plans to apply for a favorable determination letter, which provides assurance to a plan sponsor that its plan complies in form with Section 403(b) of the Internal Revenue Code (Code) and applicable regulations.

    In depth

    The IRS has long permitted sponsors of individually designed pension and 401(k) retirement plans qualified under Section 401(a) of the Code to obtain a favorable determination letter on the status of their tax-qualified retirement plan. A determination letter expresses the IRS’s opinion regarding the form of the plan and provides a plan sponsor with assurance that its plan complies with the applicable requirements of the Code and regulations. Plan sponsors routinely use determination letters to verify the plan’s status as a tax-qualified plan for auditors, during transactions and for other qualified plans to transmit rollovers.

    As of June 1, 2023, the IRS program now extends to certain individually designed (i.e., drafted without relying on a vendor prototype or volume submitter document) retirement plans qualified under Section 403(b) of the Code. Since 2009, most 403(b) plans have required a written plan document, but plan sponsors could not obtain the IRS’s opinion that the form of the plan follows the Code’s requirements. 403(b) plan sponsors can now obtain an initial determination letter under the IRS program.

    However, the new determination letter program does have several limitations. Determination letter applications are limited to an initial review of individually designed 403(b) plans (including most long-standing 403(b) plans that could not apply previously) and terminating 403(b) plans. In other words, a plan cannot file for a new determination letter every few years. In the future, the IRS may open the determination letter program to 403(b) plans for other circumstances.

    The IRS provided staggered eligibility periods for plan sponsors to begin submitting applications based on the last digit of the plan sponsor’s Employer Identification Number (EIN):

    • EIN ending in 1, 2 or 3: Submissions allowed beginning June 1, 2023.
    • EIN ending in 4, 5, 6 or 7: Submissions allowed beginning June 1, 2024.
    • EIN ending in 8, 9 or 10: Submissions allowed beginning June 1, 2025.

    For sponsors applying for a determination letter upon termination, applications can be submitted at any time on or after June 1, 2023. A plan sponsor can still submit its application if the plan was terminated before June 1, 2023, if the submission is no later than one year after either the plan’s termination date or when the action terminating the plan occurred. However, if the plan assets are fully distributed after plan termination, as is most often the case, then the plan sponsor must apply for the determination letter within 12 months.

    CONCLUSION 

    Most 403(b) plan sponsors that utilize individually designed plans will want to take advantage of the IRS program to apply for a determination letter. If you are a 403(b)-plan sponsor, the McDermott employee benefits team can assist in reviewing your current plan documents to determine your eligibility to file and prepare the materials required for a determination letter application submission to the IRS.

    Authors

    Todd A. Solomon

    Partner

    Chicago

    Jeffrey M. Holdvogt

    Partner

    Chicago

    Haley M. Dow

    Associate

    Chicago

    More insights

  • On the Stand with Richard Salgado

    On the Stand with Richard Salgado

    ARTICLE

    On the Stand with Richard Salgado

    October 23, 2023

    Read time: 6 min

    Key takeaways
    Overview

    As head of the Dallas Litigation Practice Group, Richard Salgado joined McDermott to build a preeminent litigation practice in Texas. He has first-chaired 13 jury trials and presented oral arguments in more than two dozen appeals. Richard represents clients in complex, bet-the-company disputes ranging from commercial litigation to tort, intellectual property and regulatory matters with amounts at issue often in the billions of dollars.

    In this Q&A, Richard shares why being a nice person matters during trial, how he helps clients overcome pretrial jitters and why clients should add him to their trial team at the eleventh hour.

    In depth

    How has your career evolved since you became a lawyer?

    I started as an appellate lawyer. I clerked on the US Court of Appeals for the Fifth Circuit after law school, and I loved everything about it. After my clerkship, I joined the issues and appeals group at a global law firm. I hadn’t thought much about trial work and being a trial lawyer. But as I attended trials as appellate counsel, I watched the trial lawyers and thought, “I can do that. That looks like fun.” In fact, before law school, my background was in theater and film. I almost got a Master of Fine Arts in film.  I had more experience as a director than an actor, but I understood the art of performing in front of an audience and telling a story. It’s all very similar to being a trial lawyer.

    The real transition happened eight or nine years ago when I went to trial with a major client as their appellate lawyer. At the hearing right before trial, the plaintiff’s lawyer was bullying and pushing around the lead defense lawyer, practically eating his lunch. The client pulled me aside afterward and decided on the spot to appoint me first chair for the three-week trial on 72 hours’ notice. I went back to the hotel, called my wife, fell apart for a few hours, picked myself up, tried my first case, won it and never looked back.

    And now, years later, I’m building out McDermott’s complex litigation and trial practice in Texas. The Texas market is expanding with a diverse array of client needs, and it’s an exciting step in my career to be part of broadening our client base while doing what I love.

    What is one thing every trial lawyer should know about being in the courtroom?

    Every moment you’re around the courthouse, you’re being watched. Your behavior outside of the courtroom matters—even in the parking lot. If you skip into the courthouse while a paralegal struggles to carry eight boxes, the jury sees that. If you’re rude to a security guard, the jury sees that. If you react in a certain way to opposing counsel, the jury sees that.

    When I’m in a public area of any kind during trial, I make sure I am the most respectful, kind and pleasant human being. Of course, that’s how we should always act no matter who is watching! But with the jurors, perception is everything, and they form opinions based on split-second and sometimes unfair observations (including your resting face). I don’t want to exhibit any signs that could come off as offensive to the jury in any way.

    How do you prepare for each day when you’re at trial?

    Being prepared means knowing as much as possible so you are never surprised. It needs to feel spontaneous, but it is based on hundreds—if not thousands—of hours of preparation.

    It’s also critical to maintain emotional balance, which is not always easy during trial. I have a tradition to support that balance: The first thing I do when I finish trial each day is go for a run and clear my head. I also FaceTime my family each evening. Then I feel like a human being again, and I can resume making sure I’m absolutely prepared for the next day. There are many far more important reasons to do this, but if you need a purely Machiavellian reason, the simple truth is jurors don’t connect well with soulless cyborgs.

    What is a common issue you see clients face going into trial, and how do you handle it?

    I often see a lot of anxiety. In the days and weeks leading up to jury trial, many clients start to panic. They imagine worst-case scenarios and runaway jury awards. No matter how strong their case is, as the clock ticks closer and closer, they get scared and want to settle on terms they never would have rationally considered. Pathos overrides logos.

    Part of my job is to reassure the client that we’re ready. I help them understand that we’ve already addressed those fears and anxieties—we’ve known about them for months. If there are surprises, we’ll be ready.

    It all boils down to preparation. Preparation is the antidote to fear and terror, which is what most clients feel in the moments leading up to trial.

    What is one thing about your practice that you’d like people to know?

    I can jump into cases really close to trial. It’s a distinct skill and doesn’t faze me.

    I joined more than half of my 13 first-chair experiences within two to three months of trial, and that’s uncommon. In another half-dozen trials that I jumped into, we resolved either with a settlement or on motions immediately before trial—sometimes even after picking a jury. Very recently, I entered a case in Texas with just a month to spare. I believe it’s an advantage, because I’m seeing the case the same way the jury will, without years of history and minutiae (none of which the jury will care about) weighing me down as I prepare.

    No matter when I join a case, when I’m going to trial for a client, that client is my absolute priority. I am there for that client before anything else, and I am not simply doing a job. I am invested, and I care. Their priorities are my priorities. Being completely in sync in that way is essential.


    Check out more trial lawyer interviews in our On the Stand series.

    Authors

    Richard Salgado

    Partner

    Dallas, Austin

    More insights

  • Healthcare Regulatory Check-up Newsletter | September 2023 Recap

    Healthcare Regulatory Check-up Newsletter | September 2023 Recap

    ARTICLE / REPORT

    Healthcare Regulatory Check-up Newsletter | September 2023 Recap

    October 23, 2023

    Read time: 2 min

    Overview

    This issue of McDermott’s Healthcare Regulatory Check-Up highlights regulatory activity for September 2023. We discuss several criminal and civil enforcement actions that involve violations of the False Claims Act (FCA), the Anti-Kickback Statute (AKS) and the Stark Law. We also review several regulatory updates and a recent unfavorable advisory opinion issued by the Office of the Inspector General (OIG).

    In depth
    Tabs

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Monica Wallace

    Partner

    Chicago

    MaryKathryn Hurd

    Senior Knowledge Management Manager

    Washington, DC

    More insights
    Endnotes

  • The Concept of Gun Jumping under German Foreign Investment Control | Practical Guidance in Ongoing FDI Proceedings

    The Concept of Gun Jumping under German Foreign Investment Control | Practical Guidance in Ongoing FDI Proceedings

    ARTICLE / CLIENT ALERT

    The Concept of Gun Jumping under German Foreign Investment Control | Practical Guidance in Ongoing FDI Proceedings

    October 21, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Under the German FDI regime, the competent ministry (BMWK) may review foreign investments in domestic target companies above certain thresholds. The legislator has extended the scope of notification obligations over the past few years, with the consequence that (i) acquirers must in an increasing number of cases notify the BMWK immediately after signing and (ii) clearance of the transaction then qualifies as a statutory closing condition. Notification obligations typically depend on the type of the domestic target business, more specifically if business activities of the target in Germany are considered sensitive from a public order and security standpoint (e.g. operation of critical infrastructures, development and manufacturing of semiconductor technology, AI-based solutions, robotics, IT security, weapons and armaments).

    Since 2020, German law has prohibited the factual completion of transactions that are subject to a notification obligation before the BMWK grants clearance. Similar to the gun jumping concept established for merger control reviews across the globe, the parties are not allowed to take certain measures that could be considered as a premature closing of the transaction (the so-called standstill obligation). The antitrust authorities pursue a rather broad concept of what constitutes an infringement of the standstill obligation, so that the acquirer must avoid the possibility to determine the target’s business before closing. This includes scenarios such as extensive pre-closing planning discussions and preparations as well as excessive information exchange.

    While gun jumping rules under German merger control have existed since the adoption of the national merger control in 1973, the legislator only rolled out a corresponding concept under the FDI regime during the COVID-19 pandemic. The purpose of the reform was to prevent the parties from creating irreversible circumstances, such as (i) a potential technology outflow from Germany to third-party countries and (ii) foreign investors gaining access to security-related information before clearance of the transaction.

    In depth

    In the absence of case law and official authority guidance, there is uncertainty in practice as to how the FDI gun jumping rules must be interpreted. Based on the wording of the applicable regulations, the FDI gun jumping rules appear to be much narrower in scope than their equivalent under merger control. They are essentially limited to two types of prohibited pre-closing measures:

    No premature exercise of voting rights

    It is prohibited for foreign investors to factually exercise control already before clearance of the acquisition. The acquirer shall not yet act like an owner of the German target company. Examples include the transfer of bearer securities, the endorsement of registered securities and agreements on the exercise of voting rights. The parties may, on the other hand, agree on a customary reserved matters catalogue which provides the acquirer with an adequate level of comfort that the seller maintains the business “as is” in the transition period until closing and, thus, also during FDI review proceedings. From a merger control perspective, such clauses are permissible in principle but should not be construed in a way that the acquirer prematurely gains control over the target. Therefore, it is recommended – on a case-by-case assessment – to strictly limit the reserved matters to what is necessary to ensure that the value of the target is maintained. There are strong reasons to argue that these principles likewise apply in the context of the FDI gun jumping rules.

    No premature disclosure of sensitive information

    The acquirer may not yet receive sensitive information about the target before clearance of the acquisition if such information affects public order and security interests. The scope of this prohibition extends only to those business activities that trigger a notification obligation, including technical know-how and insights. There are strong reasons to argue that it does not refer to purely commercial information typically exchanged in the context of the due diligence process. In the event that sensitive information must be exchanged between the parties, e.g., to respond to requests from the BMWK in the context of ongoing FDI proceedings, the gun jumping rules should be interpreted more liberally.

    Unlike in merger control, which provides fines for companies only, gun jumping under the German FDI regime may qualify as a criminal offense with potentially severe legal and reputational consequences for the management and other persons involved.

    Authors

    Dr. Laura Stammwitz

    Partner

    Frankfurt

    More insights